Evidence map›Paper›PMID 42440446›Full record

ArticleKidney international reports2026

Phenotypic Spectrum of HNF4α-Associated Fanconi Renotubular Syndrome.

Francesco Emma, Detlef Böckenhauer, Andrew J Mallett, Rupesh Raina, Sidharth K Sethi, Gerlineke Hawkins-van der Cingel, Martin Bald, Leyat Tal, Martin Pohl, Marie Courbebaisse and 13 more

Abstract read
In one paragraph

Article in Kidney international reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Francesco EmmaDivision of Nephrology, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.
Detlef BöckenhauerPaediatric Nephrology, Great Ormond Street Hospital for Children and UCL Centre for Kidney and Bladder Health, University College London, London, UK.
Andrew J MallettDepartment of Renal Medicine, Townsville University Hospital, Townsville, Queensland, Australia.
Rupesh RainaDepartment of Pediatric Nephrology, Akron Children's Hospital, and Cleveland Clinic Foundation, Cleveland, Ohio, USA.
Sidharth K SethiDepartment of Pediatric Nephrology, Artemis Hospital, Gurgaon, Haryana, India.
Gerlineke Hawkins-van der CingelDepartment of Nephrology and Medical Intensive Care, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Martin BaldDepartment of Pediatric Nephrology, Olga-Hospital, Clinic of Stuttgart, Stuttgart, Germany.
Leyat TalDepartment of Pediatrics, Division of Nephrology, Baylor College of Medicine, Houston, TX.
Martin PohlDepartment of General Pediatrics, Faculty of Medicine, Adolescent Medicine and Neonatology, Medical Center, University of Freiburg, Breisgau, Germany.
Marie CourbebaisseService de Physiologie, Hôpital Européen Georges Pompidou Université Paris Cité, Paris, France.
Marguerite HureauxINSERM U1151 Centre de Référence des Maladies Rénales Héréditaires de l'Enfant et de l'Adulte, Paris, France.
Robert KletaPaediatric Nephrology, Great Ormond Street Hospital for Children and UCL Centre for Kidney and Bladder Health, University College London, London, UK.
Barbara RuggieroDivision of Nephrology, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.
Marina AksenovaNephrology Department, Y.Veltischev Research and Clinical Institute for Pediatrics and Pediatric Surgery at the Pirogov Russian National Research Medical University, Mascow, Russian Republic.
Héctor RíosDepartment of Pediatric Nephrology, Vall d'Hebron University Hospital, Barcelona, Spain.
Greg WilsonMater Kidney Health Service, Mater Hospital, Brisbane, Queensland, Australia.
Kay LattaClementine Kinderhospital, Frankfurt am Main, Germany.
Justine BacchettaCentre de référence des maladies rares du métabolisme du calcium et du phosphate - Hôpital Femme Mère Enfant, Hospices Civils de Lyon-OSCAR-ERN BOND, Lyon, France.
Francesco TrepiccioneDepartment of Medical Translational Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.
Martin KonradDepartment of General Pediatrics, University Children's Hospital, Münster, Germany.
Aurélia Bertholet-ThomasCentre de Référence des Maladies Rénales Rares - MAREGE, Filière ORKID (Orphan Kidney Diseases), Hôpital Femme Mère Enfant, Hospices Civils de Lyon, France.
Gema AricetaDepartment of Pediatric Nephrology, Vall d'Hebron University Hospital, Barcelona, Spain.
Karl P SchlingmannDepartment of General Pediatrics, University Children's Hospital, Münster, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Fanconi renal tubular syndrome 4 (FRTS4) is a very rare, autosomal dominant disease caused by heterozygous variants affecting the arginine residue at position 85 of the Methods: We conducted an international, physician-based, anonymous data collection within the European Rare Kidney Disease Reference Network and beyond, focusing on clinical features, treatment, and the progression of chronic kidney disease (CKD) in patients with FRTS4. Results: Overall, we collected data on 25 patients. Twenty-four of these carried the classic p.R85W variant, and 1 carried a new p.R85L variant. Prematurity and macrosomia at birth were frequently observed. Congenital hyperinsulinism with postnatal hypoglycemia was documented in 14 of 21 patients. Renal Fanconi syndrome was diagnosed at a median age of 1.5 (interquartile range: 0.1-4.3) years. Common symptoms included failure to thrive (13/23), rickets (9/25), nephrocalcinosis (12/25), and CKD before age 10 years (13/19). All tested patients exhibited low-molecular-weight proteinuria, aminoaciduria, and glycosuria. Hyperphosphaturia, metabolic acidosis, and hypercalciuria were present in most patients. The main extrarenal symptoms were liver abnormalities and cardiac septal defects. During a median follow-up period of 8.1 years kidney function deteriorated slowly. All adult patients progressed to CKD stage 3. Four patients developed maturity-onset diabetes of the young (MODY). Conclusion: These findings provide a comprehensive picture of FRTS4. The disease should be suspected in children presenting with renal Fanconi syndrome, especially if there was fetal macrosomia and if they have experienced neonatal hypoglycemia. Progression of CKD is invariably observed, and liver and cardiac involvement should always be investigated.

Indexed as

chronic kidney diseasecongenital hyperinsulinismFanconi syndromematurity onset diabetes of the youngneonatal hypoglycemiatranscription factor

Identifiers

PMID42440446
PMCPMC13333293

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.